Equity research analysts expect Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to report $ 743.25 million in revenue for the current fiscal quarter, Zacks reports. Six analysts estimated Jazz Pharmaceuticals’ profit, with the lowest revenue estimate of $ 727.29 million and the highest estimate of $ 767.38 million. Jazz Pharmaceuticals reported sales of $ 562.44 million in the same quarter last year, indicating a positive growth rate of 32.1% year-over-year. The company is expected to release its next results on Tuesday, August 3.
On average, analysts expect Jazz Pharmaceuticals to report annual revenue of $ 3.11 billion for the current fiscal year, with estimates ranging from $ 3.06 billion to $ 3.14 billion. of dollars. For next year, analysts predict the company will post sales of $ 3.83 billion, with estimates ranging from $ 3.70 billion to $ 4.01 billion. Zacks sales averages are an average based on a survey of research analysts who follow Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ: JAZZ) last released its quarterly earnings data on Tuesday, May 4. The specialty pharmaceutical company reported EPS of $ 3.92 for the quarter, beating the consensus estimate of $ 3.09 by $ 0.83. Jazz Pharmaceuticals had a net margin of 21.27% and a return on equity of 22.95%. The company posted revenue of $ 607.58 million in the quarter, compared to analysts’ estimates of $ 613.07 million. During the same period of the previous year, the company achieved earnings per share of $ 0.45. Jazz Pharmaceuticals quarterly sales increased 13.6% compared to the same quarter last year.
Several brokerages have published reports on JAZZ. Zacks Investment Research downgraded Jazz Pharmaceuticals from a âcustodyâ rating to a âstrong sellâ rating and set a target price of $ 150.00 for the company. in a research report on Tuesday, June 22. HC Wainwright raised its target price on Jazz Pharmaceuticals shares from $ 212.00 to $ 220.00 and assigned the company a “buy” rating in a research note on Monday, June 21. Stifel Nicolaus raised his price target for Jazz Pharmaceuticals shares from $ 195.00 to $ 202.00 and assigned the company a “buy” rating in a research note on Wednesday, April 14. TheStreet raised Jazz Pharmaceuticals shares from a âc +â rating to a âbâ rating in a research note on Wednesday, May 12. Finally, Barclays increased its price target for Jazz Pharmaceuticals from $ 235.00 to $ 250.00 and rated the company as “overweight” in a report released on Tuesday, June 22. Two analysts gave the stock a sell rating, one assigned a conservation rating and fourteen a buy rating to the stock. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $ 195.25.
Meanwhile, CEO Bruce C. Cozadd sold 1,500 shares in a trade that took place on Monday, May 3. The shares were sold at an average price of $ 164.24, for a total trade of $ 246,360.00. Following the closing of the sale, the CEO now owns 321,841 shares of the company, valued at $ 52,859,165.84. The transaction was disclosed in a file with the Securities & Exchange Commission, which is available at this link. Additionally, CEO Bruce C. Cozadd sold 500 shares in a trade that took place on Wednesday, May 5th. The shares were sold at an average price of $ 170.00, for a total trade of $ 85,000.00. Following the sale, the CEO now directly owns 321,841 shares of the company, valued at approximately $ 54,712,970. Disclosure of this sale can be found here. 4.80% of the shares are currently held by insiders of the company.
A number of institutional investors have recently increased or reduced their stakes in the company. Sowell Financial Services LLC increased its holdings of Jazz Pharmaceuticals shares by 81.1% in the first quarter. Sowell Financial Services LLC now owns 259 shares of the specialty pharmaceutical company valued at $ 45,000 after purchasing 116 additional shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in the shares of Jazz Pharmaceuticals by 29.1% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 297 shares of the specialty pharmaceutical company valued at $ 49,000 after purchasing 67 additional shares in the last quarter. CWM LLC increased its stake in the shares of Jazz Pharmaceuticals by 38.0% in the first quarter. CWM LLC now owns 356 shares of the specialty pharmaceutical company valued at $ 59,000 after purchasing an additional 98 shares in the last quarter. Cutler Group LP purchased a new position in Jazz Pharmaceuticals shares in the first quarter valued at approximately $ 65,000. Finally, IndexIQ Advisors LLC increased its stake in the shares of Jazz Pharmaceuticals by 15.0% in the first quarter. IndexIQ Advisors LLC now owns 865 shares of the specialty pharmaceutical company valued at $ 142,000 after purchasing 113 additional shares in the last quarter. Institutional investors hold 92.02% of the shares of the company.
Shares of NASDAQ: JAZZ opened at $ 181.50 on Tuesday. Jazz Pharmaceuticals has a one-year low at $ 103.46 and a one-year high at $ 189.00. The company’s 50-day simple moving average is $ 176.48. The stock has a market cap of $ 10.33 billion, a price / earnings ratio of 19.90, a PEG ratio of 0.97 and a beta of 1.04. The company has a quick ratio of 4.06, a current ratio of 4.21, and a debt ratio of 0.49.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceuticals for various unmet medical needs in the United States, Europe and internationally. The company has a portfolio of products and product candidates focused on areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
Further reading: certificate of deposit (CD) for risk averse investors?
Get a Free Copy of Zacks’ Research Report on Jazz Pharmaceuticals (JAZZ)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [emailÂ protected]
Featured article: What does a bar chart mean to investors?
7 Precious Metals Stocks That Will Keep Your Portfolio On Trend
The growing acceptance of cryptocurrency is starting to cause mainstream investors to rethink their idea of ââ’store of value’. The fashionable possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are all the rage like the latest fad.
However, the thing about fashion is that the more things change, the more things stay the same. Just like the simple black dress that never goes out of style, so do stocks of precious metals. One way to think about it would be to say that the existence of a growing cryptocurrency market does not change the value of precious metals.
Precious metals have long been known as a safe haven in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices jumped about 30%, surpassing the $ 2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were dropping.
And precious metals have also been seen as a hedge against inflation, which seems to be more of a certainty with the Federal Reserve’s commitment to keep interest rates at historically low rates until 2023.
Whether you are looking to take your first steps in building a precious metals portfolio or want to refine the one you own, we think this special presentation is a good place to start your research. We’ve identified seven precious metals stocks looking to maintain their appeal in 2021.
Check out the “7 Precious Metals Stocks That Will Keep Your Portfolio On Trend.”